Investor Relations
Press Releases

Press Releases

Press Releases

August 24, 2020
Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement
- Combined companies to leverage their common scientific expertise in protein misfolding -   -Focus on Yumanity's lead clinical program in Parkinson's disease and transformative pipeline of disease-modifying treatments for neurogenerative disorders -   - Companies to host joint conference call
August 6, 2020
Proteostasis Therapeutics Reports Second Quarter 2020 Financial Results
BOSTON , Aug. 6, 2020 /PRNewswire/ --  Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced financial results for the second quarter ended June
Displaying 1 - 10 of 11

Shareholder Tools